INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Commercial Readiness: The ROI Of Defragmented Supply Chains

  Clinical-stage supply chains often hide costs that emerge at commercial scale. Standardizing systems, documentation, and providers can reduce variability and improve long-term performance.

• Extended Manufacturability: Why Cryopreservation Is A Commercial Enabler

  Cryopreserved starting materials separate collection from manufacturing, improving capacity planning, enabling broader geographic reach, and redefining commercial readiness for cell therapies.

• Navigating Outsourced Pharmaceutical Testing Through Today's Geopolitical Uncertainty

  Geopolitical shocks are reshaping outsourced pharmaceutical testing. Learn how procurement teams can strengthen resilience and protect continuity.

• Is Your Supply Chain Ready For The End Of Class VI?

  Revisions to USP <87> and <88> update biological reactivity testing — changes that are especially important for companies that rely on single-use technology.

• Avoiding The Pitfalls: 5 Lessons For Cell Therapy Manufacturing Success

  Cell therapy programs often stall between clinical and commercial supply because of manufacturing readiness, not clinical performance. Five recurring pitfalls, from partner choice to automation, show where early planning matters.

• Protective Shell For 2D Bags: Engineered For Mechanical Protection

  Protect frozen single-use bag assemblies from movement and handling stress with rigid secondary packaging, dedicated foam immobilization, and efficient plate-freezing heat transfer.

• Scaling Cryopreservation Without Wasting MSC Product

  During this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. turn the discussion to the practical challenges of cryopreserving large cell volumes, manufacturing capacity, and how companies can avoid introducing major changes as they move toward commercialization.

• Integrated Services That Pass Inspections

  Standardized supply chain workflows reduce risk, protect biological integrity, and enable compliant scaling from clinical trials through commercialization.

• Selecting A Central Lab Network For Radiopharmaceutical Readiness

  A wave of late-stage radiopharmaceutical trials is straining lab infrastructure concentrated in a handful of academic centers, limiting site diversity, expertise, and trial capacity nationwide.

• Central Laboratory Solutions

  Global clinical trials need central laboratory networks able to scale across countries while keeping biomarker and biospecimen data consistent from one study site to the next.